Israel’s Azura Ophthalmics is tackling Dry Eye Disease (DED) by preventing its root cause – Dysfunction of the Meibomian Gland or MGD. Azura has reported good results during the Phase 2 clinical trials of its AZR-MD-001 ointment, applied to the lower eyelid.
https://en.globes.co.il/en/article-dry-eye-treatment-co-azura-ophthalmics-raises-20m-1001346802
https://finance.yahoo.com/news/azura-ophthalmics-announces-primary-endpoints-130000591.html